Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2
and ERBB3
Authors
Keywords
-
Journal
CANCER
Volume 124, Issue 7, Pages 1358-1373
Publisher
Wiley
Online
2018-01-17
DOI
10.1002/cncr.31125
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway.
- (2017) Herbert Hurwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib
- (2017) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis
- (2016) Elie Kassouf et al. BIODRUGS
- HER3 as a Therapeutic Target in Cancer
- (2016) Niki Karachaliou et al. BIODRUGS
- Cancer treatment and survivorship statistics, 2016
- (2016) Kimberly D. Miller et al. CA-A CANCER JOURNAL FOR CLINICIANS
- NonamplificationERBB2genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies
- (2016) Jeffrey S. Ross et al. CANCER
- Spectrum of Gene Mutations in Colorectal Cancer
- (2016) Rodrigo Dienstmann et al. CANCER JOURNAL
- The evolving role of microsatellite instability in colorectal cancer: A review
- (2016) Fabio Gelsomino et al. CANCER TREATMENT REVIEWS
- From Molecular Biology to Clinical Trials: Toward Personalized Colorectal Cancer Therapy
- (2016) Sabina Palma et al. Clinical Colorectal Cancer
- The state of regional therapy in the management of metastatic colorectal cancer to the liver
- (2016) May Cho et al. Expert Review of Anticancer Therapy
- Global patterns and trends in colorectal cancer incidence and mortality
- (2016) Melina Arnold et al. GUT
- HGVS Recommendations for the Description of Sequence Variants: 2016 Update
- (2016) Johan T. den Dunnen et al. HUMAN MUTATION
- Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations
- (2016) Noura J. Choudhury et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials
- (2016) Susan D Richman et al. JOURNAL OF PATHOLOGY
- Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer
- (2016) Aparna Parikh et al. Journal of the National Comprehensive Cancer Network
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
- (2016) Andrea Sartore-Bianchi et al. LANCET ONCOLOGY
- Targeted molecular profiling of rare genetic alterations in colorectal cancer using next-generation sequencing
- (2016) Mayank Jauhri et al. MEDICAL ONCOLOGY
- Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer
- (2016) Andrew Rankin et al. ONCOLOGIST
- BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis
- (2016) Soo Kyung Nam et al. PLoS One
- How the Lab is Changing Our View of Colorectal Cancer
- (2016) Chiara Cremolini et al. TUMORI
- Advances in targeted and immunobased therapies for colorectal cancer in the genomic era
- (2016) Heng Seow et al. OncoTargets and Therapy
- Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
- (2016) Garrett S. Barry et al. Oncotarget
- Targeted Therapy of Colorectal Cancer
- (2016) Andreas Seeber et al. Oncology Research and Treatment
- Role of targeted therapy in metastatic colorectal cancer
- (2016) Yoshihito Ohhara et al. World Journal of Gastrointestinal Oncology
- How the Lab is Changing Our View of Colorectal Cancer
- (2016) Chiara Cremolini et al. TUMORI JOURNAL
- Response to dual HER2 blockade in a patient withHER3-mutant metastatic breast cancer
- (2015) F.-C. Bidard et al. ANNALS OF ONCOLOGY
- Lung cancer patients withHER2mutations treated with chemotherapy andHER2-targeted drugs: results from the European EUHER2 cohort
- (2015) J. Mazières et al. ANNALS OF ONCOLOGY
- Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites
- (2015) Wafik S. El-Deiry et al. CANCER BIOLOGY & THERAPY
- Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer
- (2015) Michael Kloth et al. GUT
- Genetic mutations in human rectal cancers detected by targeted sequencing
- (2015) Jun Bai et al. JOURNAL OF HUMAN GENETICS
- HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor
- (2015) Noa Efrat Ben-Baruch et al. Journal of the National Comprehensive Cancer Network
- Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
- (2015) Giulia Siravegna et al. NATURE MEDICINE
- Prospective Comprehensive Genomic Profiling of Advanced Gastric Carcinoma Cases Reveals Frequent Clinically Relevant Genomic Alterations and New Routes for Targeted Therapies
- (2015) S. M. Ali et al. ONCOLOGIST
- HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
- (2015) S. M. Kavuri et al. Cancer Discovery
- HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer
- (2015) Naoki Takegawa et al. Oncotarget
- Colorectal Cancer Survival Gains and Novel Treatment Regimens
- (2015) Irfan Jawed et al. JAMA Oncology
- Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers
- (2015) Nicky D’Haene et al. PLoS One
- Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo
- (2015) Siao-Syun Guan et al. Oncotarget
- Whole genome sequencing reveals potential targets for therapy in patients with refractory KRASmutated metastatic colorectal cancer
- (2014) Vijayalakshmi Shanmugam et al. BMC Medical Genomics
- Molecular Pathways: HER3 Targeted Therapy
- (2014) K. Gala et al. CLINICAL CANCER RESEARCH
- Response of an ERBB2-Mutated Inflammatory Breast Carcinoma to Human Epidermal Growth Factor Receptor 2–Targeted Therapy
- (2014) Siraj M. Ali et al. JOURNAL OF CLINICAL ONCOLOGY
- ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models
- (2014) L. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- COSMIC: exploring the world's knowledge of somatic mutations in human cancer
- (2014) Simon A. Forbes et al. NUCLEIC ACIDS RESEARCH
- Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin
- (2014) J. Chmielecki et al. ONCOLOGIST
- Profiling Cancer Gene Mutations in Clinical Formalin-Fixed, Paraffin-Embedded Colorectal Tumor Specimens Using Targeted Next-Generation Sequencing
- (2014) L. Zhang et al. ONCOLOGIST
- HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression
- (2014) An Na Seo et al. PLoS One
- Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations
- (2014) P. Littlefield et al. Science Signaling
- A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial
- (2013) A. Johnsson et al. ANNALS OF ONCOLOGY
- Intermittent versus continuous erlotinib with concomitant modified “XELOX” (q3W) in first-line treatment of metastatic colorectal cancer
- (2013) Brigette B. Y. Ma et al. CANCER
- Oncogenic ERBB3 Mutations in Human Cancers
- (2013) Bijay S. Jaiswal et al. CANCER CELL
- Relapsed Classic E-Cadherin (CDH1)-Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations
- (2013) J. S. Ross et al. CLINICAL CANCER RESEARCH
- A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma
- (2013) J. S. Ross et al. CLINICAL CANCER RESEARCH
- HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome
- (2013) F. Lédel et al. EUROPEAN JOURNAL OF CANCER
- HER2-positive gastric cancer
- (2013) Narikazu Boku Gastric Cancer
- Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients
- (2013) Douglas A. Rubinson et al. INVESTIGATIONAL NEW DRUGS
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
- (2012) H. Greulich et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- (2012) Ron Bose et al. Cancer Discovery
- High False-Negative Rate of HER2 Quantitative Reverse Transcription Polymerase Chain Reaction of the Oncotype DX Test: An Independent Quality Assurance Study
- (2011) David J. Dabbs et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review
- (2011) Orit Kaidar-Person et al. MEDICAL ONCOLOGY
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Human Splice Variant Δ16HER2 Induces Rapid Tumor Onset in a Reporter Transgenic Mouse
- (2011) Cristina Marchini et al. PLoS One
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- (2011) K. Yonesaka et al. Science Translational Medicine
- A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
- (2011) A. Bertotti et al. Cancer Discovery
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance
- (2009) D. Mitra et al. MOLECULAR CANCER THERAPEUTICS
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
- (2009) J. S. Ross et al. ONCOLOGIST
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started